AD Pipeline Update: LEO Pharma Reports Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe AD May 12, 2025
AD Pipeline Watch: First Patient Dosed in Phase 2b Clinical Trial Program of Zabalafin Hydrogel April 8, 2025
